Boston's Watchman approval on knife edge as panel vote nears
This article was originally published in Clinica
Executive Summary
It has been a long road, but US approval of Boston Scientific’s Watchman stroke-prevention device for atrial fibrillation patients is still far from assured. The left atrial appendage (LAA) closure device is due to be reviewed by an FDA advisory panel on 11 December, and the agency has put out briefing documents that are decidedly mixed, raising doubts over its eventual approval.
You may also be interested in...
What are the hottest innovations from Israel?
Israel is well-known as a medtech hot-spot, with a focus on academic research and strong government support helping the country punch well above its weight when it comes to innovative devices.
EuroPCR: St Jude and Philips talk up rival intravascular imaging techs
St Jude Medical had a heavy focus on its intravascular imaging offering at this year’s EuroPCR meeting, presenting data supporting its optical coherence tomography (OCT) technology. OCT provides intravascular images to help assess culprit lesions, which can improve stent selection and deployment, according to St Jude.
EuroPCR: Medtronic's drug-coated balloon keeps rising
A big topic at this year’s EuroPCR, held in Paris on 19-22 May, was drug-coated balloons (DCBs). One of the leaders in the field, Medtronic, presented positive data from two studies of its IN.PACT Admiral balloon, which could support an expanded indication for the device.